Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

  Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013
                            Health Care Conference

PR Newswire

SAN DIEGO, May 10, 2013

SAN DIEGO, May 10, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq:
OREX) today announced that management will present a company overview at the
Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas. The
presentation is scheduled for Wednesday, May 15^th at 1 p.m. Pacific Time. To
listen to the live webcast or a replay of the presentation, please visit the
Investor Relations section of the Company's Web site at www.orexigen.com. A
replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead product candidate is Contrave®, which
has completed Phase 3 clinical trials and for which a New Drug Application has
been submitted and reviewed by the FDA. The Company has also reached agreement
with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the
Contrave cardiovascular outcomes trial. The Company's other product candidate,
Empatic™, has completed Phase 2 clinical trials. Further information about the
Company can be found at www.orexigen.com.

Orexigen Contact:                                     Media Contact:
McDavid Stilwell                                      Denise Powell
VP, Corporate Communications and Business Development BrewLife
(858) 875-8629                                        (510) 703-9491

SOURCE Orexigen Therapeutics, Inc.

Website: http://www.orexigen.com
 
Press spacebar to pause and continue. Press esc to stop.